Yahoo Finance

EBITDA and adjusted EBITDA should not be considered in isolation or as alternatives to net income cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. You can find additional information regarding these non-GAAP measures on Slide 2 of our presentation, which is available in the Investor Relations section of our website. Reconciliation of EBITDA and adjusted EBITDA to net loss, the most comparable GAAP measure is included in that presentation as an appendix. We have not provided a reconciliation for any forward-looking non-GAAP measures referred to in this presentation as we would not be able to produce such a reconciliation without unreasonable efforts.

As we review the developments in 2022, this is an important time to remind everyone of our vision at Akumin, which is to be the partner of choice for U.S. hospitals and health systems. It's clear that hospitals and health systems are increasingly in need of outpatient solutions and capacity. Akumin is extremely well-positioned to capitalize on this trend, which as you know was part of the strategic rationale for our acquisition of Alliance Healthcare Services in late 2021. Having successfully integrated the Alliance acquisition in 2022, we are already well on our way to achieving our vision. We serve over 1,100 hospitals and 23 of the 30 biggest health systems in the country are our customers today. Hospitals represent almost 50% of our current revenues and we expect this percentage to continue to grow significantly in the coming years.

As you can see on Slide 4, outpatient service delivery is the core of our business. Over 95% of our revenues are outpatient. The shift to outpatient service delivery has been an important trend in our industry and will continue to accelerate. We recognize the significance of the shift to outpatient very early on, something that is just beginning to be fully understood and embraced in our industry. We currently operate a full suite of fixed site and mobile services, which are available to hospitals and health systems. Our asset base is strategically located with dense coverage in key markets, making them well suited to partner with hospitals in these regions. Importantly, we also leverage technology to provide clinical standardization and operational excellence, which enables us to deliver efficient and cost-effective outpatient solutions to hospitals and health systems while providing outstanding patient care and patient experience.

2022 was a busy year for Akumin. Our focus in 2022 was to streamline the organization through a number of transformational initiatives to build a solid foundation for future growth. These included eliminating functional duplication, rationalization of existing facilities and hiring key leaders, including our new CFO, our new Head of Oncology and our new Chief Revenue Officer. We also repositioned our oncology division after an extensive review. These efforts resulted in over $20 million in organizational savings. And as we mentioned in our Q3 call, there is more to come on that front. It's important to note that while we were implementing these changes as part of our organizational transformation, we faced significant industry challenges, specifically in the areas of labor availability and cost inflation.

These issues impacted everyone in healthcare industry and Akumin was not immune. The clinical labor shortage was a unique challenge. Despite robust demand the lack of labor availability restricted our ability to perform procedures in many cases, therefore negatively impacting our results both on the revenue and the cost side. Fortunately, the environment has improved somewhat thus far in 2023. And we are very optimistic that the worst is behind us. As I mentioned, we were affected in 2022 by a number of factors, including labor constraints and cost inflation. On Slide 6, we have highlighted the factors which contributed to our revenue growth in 2022 as compared to our pro forma revenues in 2021. As you can see, $10 million of our revenue growth was attributable to the increased cost of specialty tracers, which we were able to pass through.

In our Radiology segment, our revenue grew by $19.6 million over 2021 levels despite the labor headwinds we experienced and the disruption caused by Hurricane Ian in many of our Florida locations. Unfortunately, our Radiology growth was offset by decline in revenues in our higher margin oncology segment. This was primarily a result of significantly reduced business development activities as we undertook the review and facility closures associated with the repositioning of this segment. Going forward, we are excited about the organic growth outlook in our Radiology segment as the clinical labor shortage has significantly improved. We are also seeing many opportunities for growth and partnerships with hospitals in our Oncology segment now that the repositioning is complete.

Turning to the cost side. On Slide 7, you can see the many factors which increased our cost in 2022 as compared to our pro forma results in 2021. As you can see, employee compensation costs came down by $11 million as we implemented our Phase 1 synergy initiatives, which were primarily focused on eliminating functional duplication in the organization. As we have mentioned in the past, these initiatives really commenced midyear. And as such, I am pleased that we have now achieved our targeted Phase 1 synergy run-rate of $23 million. While these synergies positively impacted our performance in 2022, they were more than offset by cost inflation in other areas of the business. We are able to recoup some cost increases, such as specialty tracers which were up over $10 million in 2022, but were passed through, as I highlighted earlier on the previous slide.

Note that part of our third-party and professional service costs were related to our increased use of contracted labor and increased outsourcing in response to labor constraints during the year. Many of the other cost increases we experienced in the year were a function of the inflationary environment we are in. We will obviously look to contain these costs going forward to the extent that they are within our control. Note that we have highlighted the variable and fixed costs on the chart to help illustrate the cost categories and give you a sense of the high operating leverage in our business. Slide 8 helps to really illustrate this operating leverage. Given the relatively high fixed costs associated with our service delivery would benefit significantly from same-store organic volume growth.

As you can see, the incremental margin contribution from organic revenue growth is at least 50%. Given that a portion of our employee compensation is actually fixed, including corporate back office and frontline employees. As we illustrated on Slide 6, the factors that contributed to revenue growth in 2022 did not result in meaningful margin contribution. For example, there is no margin contribution on increased rate of revenues. And our growth radiology was offset by the decline in higher margin oncology revenue. Going forward, organic growth in both radiology and oncology will generate more than 50% margin contribution. Many of the strategic initiatives we have underway will enable us to leverage our scale and capacity to drive additional volumes through our facilities, which will obviously have a meaningful impact on our financial performance.

Slide 9 highlights some of these key strategic priorities for 2023 and beyond. As we discussed in our Q3 call, we have already identified an additional $25 million in synergies, which we expect to be captured in Phases 2 and 3 of our integration plan during 2023. As you can see, our strategic initiatives are focused on improving productivity and efficiency around the themes of clinical standardization and operational excellence. Same-store growth is a key focus for our organization, including commercial excellence, sales effectiveness and the optimization of our scheduling and revenue cycle to efficiently respond to increased demand for our services. We are also focused on leveraging technology to address the shortage of clinical staff standardized clinical protocols and workflows and dramatically improve the patient experience.

Photo by National Cancer Institute on Unsplash

The investment we made in our patient journey platform is an example. All of these initiatives are centered around addressing the key challenges faced by all of our industry stakeholders, including hospitals, payers, referring physicians and patients. Turning to our Q4 results on Slide 10, you can see the same-store consolidated volume growth in our key radiology service lines and our patient starts in our oncology division versus our pro forma results in Q4 2021. Specifically, our MRI volumes were down slightly by 0.3%, again primarily as a result of clinical staff shortages that persisted in some of our markets in the quarter. Our PET/CT volumes were up an impressive 7.8%, PET/CT less impacted by labor constraints, given the more technical skill set in that modality.

Total oncology patient starts were up 8% as momentum builds in this segment following the review and repositioning, which were completed in Q2 and Q3. Q4 revenue of $184.6 million was up $5.2 million or 3% increase from $179.4 million in the fourth quarter of last year. Adjusted EBITDA of $37.4 million was up $9.9 million, a 36% increase from $27.5 million in the fourth quarter of last year. Adjusted EBITDA margins of 20.2% were up 0.6% sequentially from 19.6% in Q3 as some of the labor and inflation constraints we experienced eased slightly in the fourth quarter. On a consolidated basis, accounts receivables at quarter end were $104.2 million versus $112.4 million at the end of Q3. This equates to 57 days of sales outstanding, up marginally from the record low level we experienced in Q3.

I will now turn the presentation over to David who will walk you through some of our key operating and financial metrics.

David Kretschmer: Thank you, Riadh. As Riadh mentioned at the outset, I will review some of the key operating and financial metrics of our business and discuss our 2023 financial guidance. Slide 11 illustrates that while the Akumin platform offers a diverse suite of services, this is very focused on areas of high growth and high value-add. You can see that over half of our €“ 54% of our radiology revenues come from MRI procedures though MRI volumes are a key driver in that segment. Akumin is also a significant player in cancer diagnosis and treatment with 24% of our radiology revenues from PET/CT and 17% of our total revenues coming from our oncology division. These modalities are critical to the delivery of quality patient care and are utilized by a variety of physician specialties across the care continuum from screening through diagnosis and treatment.

I would also note here that we consolidated our fixed site footprint in 2022 to eliminate underperforming sites. We closed a total of 7 sites during the year, although some are still on our books from an accounting perspective. We continue to evaluate all sites on an ongoing basis with a view to further rationalize where possible. Turning to Slide 12, Akumin is well-positioned to benefit from the ongoing shift to outpatient service delivery as we partner with hospitals and hospital systems transition care to lower cost sites of delivery. As you can see from the slide, we continue to generate over 95% of our revenues from outpatient procedures, with our balanced revenue mix between third-party payers for outpatient services and hospitals with no one customer representing more than 4% of our consolidated pro forma revenues.

The preferred outpatient solution provided to hospitals approximately half of our revenues come from our hospital customers. The balance is reimbursement for patient procedures from third-party commercial and government payers. For time, we expect the revenue share with hospitals to grow significantly as both existing and new hospital customers and partners search for outpatient solutions in both radiology and oncology. Turning to Slide 13, our financial performance in Akumin is primarily driven by procedure volumes. As Riadh pointed out earlier, we have high operating leverage given our cost structure, so organic growth in procedure volumes is a high-margin contributor for us. Given that the current mix of our business includes both hospitals and independent sites, we track actual scans by modality across our radiology platform.

By providing procedure volumes and mix together with the radiology procedures as a percent of revenues, we are seeking to provide more transparency into our operating and financial performance. As I noted in discussing service lines and modalities within the Radiology segment, MRI and PET/CT are the key drivers as they are by far the biggest contributors to our financial performance. On Slide 13, you can see the MRI and PET/CT procedure volumes during 2022. And to present same-store changes over the last four quarters. Note that as the market leader in PET/CT, we have seen strong growth in that modality in recent years. While MRI volumes continue to grow annually, recent quarters have seen a decline in growth as we were not able to fully capitalize on the strong MRI demand due to the labor constraints, Riadh noted earlier.

We have taken action which should mitigate those impacts in 2023. Our third quarter €˜22 was also impacted by the disruption caused by Hurricane Ian certain of our Florida locations. Note that labor constraints are less of a factor in PET/CT given the highly specialized skill set of clinical personnel for this modality. In the oncology segment, we track activity level by patient start volume. On a quarterly basis, patient starts declined sequentially on a quarter-over-quarter basis in Q2 and Q3 of 2022 as we undertook the review and reposition that business, as mentioned earlier. Growth did rebound in the fourth quarter over the prior year. We expect our oncology division to continue this improving growth trajectory over time given our compelling value proposition in the radiation therapy.

We are uniquely positioned given the many challenges, including both demand and aging fleet and capacity constraints our hospital partners face in this modality. Slide 14, you will see the annual financial performance by our Radiology and Oncology segment. Note that the pro forma results assume the legacy Akumin and Alliance businesses, the acquisition of which was completed in September 2021. And when combined for the entire period as well as adjusted for the fourth quarter 2021 divestiture of Alliance Oncology of Arizona. And you will see in the chart on the left, Radiology segment contributed $625 million of revenue for the full year 2022, representing approximately 83% of total revenues. Oncology segment contributed $125 million of revenue or approximately 17% of the total.

In our Radiology segment, our Q4 adjusted EBITDA margin was 20.2% before the allocation of corporate services. Our oncology segment is higher margin with an adjusted EBITDA margin of 34.7% before the allocation of those corporate services. Consolidated adjusted EBITDA has been essentially flat since 2020 and as we have focused on internal integration and transformation initiatives as Riadh previously discussed. Margin in 2020 were elevated in part because of the story impacts of COVID in our results, including CARES Act funding in their period. As we discussed earlier, 2022 was also negatively impacted by both the clinical labor shortage, Hurricane Ian and cost inflation resulted which resulted in a decline in adjusted EBITDA and margins. Given that the clinical labor issue is showing signs of improvement thus far in 2023, we should begin to see improving volume growth, driving revenue and adjusted EBITDA growth as year progresses as well as improvement in margin considering our significant operating leverage.

Slide 15 provides a bridge from our adjusted EBITDA to our free cash flow generation in 2022. Preliminary debt service and capital lease payments are meaningful impacts to free cash flow. Cash minority interest primarily relates to oncology joint ventures with hospital partners and is a function of the profitability of these centers, not a fixed obligation as minority interest payments increased so does their contribution to Akumin results as a partner and typically the operator of these sites. It should be noted that we incurred over $22 million of cash expenses in 2022, which were related to our restructuring efforts and are thus non-recurring. We also did benefit in 2022 from the sale of certain of our accounts receive €“ receivable for $29 million as we announced in Q3.

These two items are netted in the cash-related non-recurring column on this chart. In regards to capital expenditures, as we have noted in the past, we typically finance the majority of our CapEx through a combination of OEMs, equipment finance companies and local banks. Quarter reduces the initial cash outlay on new CapEx, but does increase capital lease or debt payments and total equipment debt or long-term debt, depending on the financing source. This is somewhat offset by a reduction in CapEx debt servicing cost and leases, which are typically 5 years in duration roll off, while that equipment can remain used for an extended period of in 10 years or more. This dynamic enables us to fund additional CapEx without layering significant financial leverage onto the business.

In 2023, we expect to reduce burden of restructuring charges together with the additional synergy capture Riadh discussed to benefit our free cash flow. This will be offset somewhat by the additional cash interest payments related to the Stonepeak subordinated notes, which go at cash pay in the latter part of the year. Turning to Slide 16, our 2023 guidance. As you can see, for 2023, we expect consolidated revenues to be in the range of $765 million to $775 million adjusted EBITDA to be in the range of $150 million to $160 million. As we had mentioned in our press release, our 2023 guidance reflects the fact that ongoing labor constraints and cost inflation persist in some of our markets, although we have also seen some improvement on these fronts so far this year.

We are encouraged by these early developments and anticipate strong demand for our services, which we expect to continue throughout 2023. In regards to CapEx, as we did in 2022, we continue to refine our capital expenditure budget to ensure the most efficient deployment of equipment, better aligned with our strategic priorities. We continually evaluate all markets prioritize those based on our criteria, that have the greatest near-term potential for growth. We expect total CapEx spend to be between $55 million and $65 million, with approximately 50% allocated to growth CapEx for new customers and sites and the balance for maintenance CapEx. Recall that we define maintenance CapEx as spend for existing customers at existing sites, while growth CapEx is primarily directed towards new hospital customer and partner acquisition as well as capacity expansion.

Our investment in new customers and sites continue to be high return, typically with a 4-year payback on growth capital. We anticipate total CapEx to be funded by approximately 20% in cash and the balance to be financed by a combination of OEMs, equipment finance companies and local banks. Higher financing costs will be a bit of a headwind in the coming year. Slide 17 illustrates our capital structure at the end of 2022. As you can see, Akumin secured leverage was 5.6x. As an organization, we are focused on reducing this over time. Near-term drivers of leverage reduction will come from the increase in EBITDA as a result of synergy capture, network rationalization, technology-driven standardization and the streamlining of deliveries, service delivery.

In addition, we have an abundance of organic revenue growth opportunities in our purview, which will meaningfully increase EBITDA given our significant operating leverage. As a result of these significant cost efficiencies and organic growth opportunities, we believe our secured leverage will decline to 4x or less than 4x over time. Note that a significant shareholder, we are highly incentivized to prudently optimize the capital structure and we will continue to evaluate options to do so as market conditions permit. I'll now turn it back over to Riadh to wrap up before we take questions.

Riadh Zine: Thanks, David. That concludes the prepared remarks portion of the presentation. I hope that it provided an informative window into the new acumen and the potential of the platform going forward. We would ask the operator to start the question-and-answer period.

Operator: Thank you. And we will go first to Noel Atkinson with Clarus.

See also 20 Biggest Publishing Companies in the World and 10 Most Profitable Cryptocurrency Stocks.

To continue reading the Q&A session, please click here.